Management of Elevated INR

Initial Assessment and Management

The American College of Cardiology recommends immediately stopping warfarin and administering oral vitamin K1 3-5 mg for INR >8.0 without bleeding, anticipating INR reduction within 24-48 hours 1
Assess for any signs of bleeding, such as gross hemorrhage, occult bleeding, intracranial hemorrhage, or bleeding at any site, and check for risk factors that increase bleeding risk, including advanced age, renal failure, alcohol use, concomitant antiplatelet agents or NSAIDs, history of stroke, and treated hypertension 1, 2, 3

The American College of Cardiology recommends stopping warfarin immediately and administering vitamin K1 3-5 mg orally, with expected INR reduction within 24-48 hours 1
Oral vitamin K1 reduces INR in 95% of patients within 24 hours 1

The American College of Cardiology recommends administering vitamin K1 10 mg by slow IV infusion immediately, along with prothrombin complex concentrate or fresh frozen plasma, for serious or life-threatening bleeding 1
Prothrombin complex concentrate is preferred over fresh frozen plasma for rapid and complete reversal 2

The American Geriatrics Society recommends exercising extreme caution with vitamin K administration in patients with mechanical heart valves, as rapid overcorrection can precipitate valve thrombosis 2, 4
Advanced age is an independent predictor of increased bleeding risk and slower INR normalization 3

The American College of Cardiology recommends avoiding high-dose vitamin K (>10 mg) routinely, as it can create warfarin resistance and induce a hypercoagulable state 1, 4
IV vitamin K should only be used when absolutely necessary, due to the risk of anaphylactoid reactions 1

The American College of Cardiology recommends investigating the cause of the elevated INR, including drug interactions, dietary changes, illness, and medication non-adherence 1, 3
Recheck INR within 24 hours after vitamin K administration to ensure appropriate response 1, 2

The American College of Cardiology recommends vitamin K administration for patients with an INR of 8.71, due to the exponential increase in bleeding risk, with the risk doubling for every 1-point INR increase above the therapeutic range, resulting in a bleeding risk of 75 per 100 patient-years at INR 6.5 5

The 2012 Chest guidelines found that vitamin K reverses supratherapeutic INRs more rapidly than withholding warfarin alone, but there was no clear evidence of benefit for patient-important outcomes, with major bleeding rates similar to those with placebo over 1-3 months, although this data was for INR 4.5-10 and no randomized trials exist for INR >10 5